Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05854303 · ClinicalTrials.gov registry record
Effect of Opioid Cessation on Opioid-Induced Esophageal Dysfunction
A clinical trial of Opioid-Induced Esophageal Dysfunction, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 26
- Enrollment target
- 1
- Study location
NCT05854303 is a study of Opioid-Induced Esophageal Dysfunction that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 26 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05854303, a study of Opioid-Induced Esophageal Dysfunction, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effect of opioid cessation on opioid-induced esophageal dysfunction (OIED).
Conditions Studied
Interventions
- BEHAVIORAL Opioid cessation
- OTHER No opioid cessation
Study Locations (1)
Minnesota
- Mayo Clinic Minnesota - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2023-09-18 |
| Est. Completion | 2026-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05854303
The ClinicalTrials.gov registry entry for NCT05854303 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Opioid-Induced Esophageal Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which Opioid cessation is the first listed.
NCT05854303 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT05854303 about?
NCT05854303 is a clinical study titled "Effect of Opioid Cessation on Opioid-Induced Esophageal Dysfunction". The purpose of this study is to evaluate the effect of opioid cessation on opioid-induced esophageal dysfunction (OIED).
What is the current status of trial NCT05854303?
This trial is currently recruiting. The enrollment target is 26 participants. The study started on 2023-09-18. Estimated completion is 2026-11.
What conditions does trial NCT05854303 study?
This clinical trial studies the following conditions: Opioid-Induced Esophageal Dysfunction.
What interventions are being tested in trial NCT05854303?
The interventions under investigation include: Opioid cessation (BEHAVIORAL), No opioid cessation (OTHER).
Who is sponsoring clinical trial NCT05854303?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05854303 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.